Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taurolidine - Geistlich

Drug Profile

Taurolidine - Geistlich

Alternative Names: PerioSept; Taurolin

Latest Information Update: 26 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Geistlich
  • Class Alkanesulfonic acids; Antibacterials; Antineoplastics; Thiadiazines
  • Mechanism of Action Lipopolysaccharide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Empyema; Peritonitis
  • Phase II Colorectal cancer
  • No development reported Periodontitis
  • Discontinued Septic shock

Most Recent Events

  • 26 Apr 2022 No development reported - Phase-II for Periodontitis (Adjunctive treatment) in USA (IV) (NDR batch 22)
  • 25 Sep 2020 Geistlich completes a phase II trial in Periodontitis (Adjunctive treatment) in USA (NCT04093895)
  • 26 Aug 2019 Phase-II clinical trials in Periodontitis (Adjunctive treatment) in USA (IV) (NCT04093895)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top